CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tango Therapeutics, a biotechnology company dedicated to delivering the next generation of targeted cancer therapies, today announced the appointment of Malte Peters, MD, to its board of directors.
Dr. Peters is Chief Development Officer at MorphoSys AG and is among the most experienced translational research and clinical development leaders in the industry, with a strong focus in oncology.
“Malte will provide valuable guidance for our target and drug discovery efforts as we advance Tango’s pipeline of targeted therapeutics, as well as strategic input as we continue to build the organization,” said Barbara Weber, MD, Tango’s Chief Executive Officer. “We’re thrilled to welcome him to our board.”
Dr. Peters joined MorphoSys AG in 2017 as Chief Development Officer and a member of the Management Board. Previously, he served as Global Head of Clinical Development of the biopharmaceuticals business unit of Sandoz International in Holzkirchen, Germany. Before joining Sandoz, Dr. Peters spent 12 years as a leader in Novartis Oncology, ultimately serving as VP, Clinical and Site Head for Basel, East Hanover, NJ and Shanghai for the early clinical development group. Earlier in his career, he worked at Merck KGaA as Director of Cancer Research and Head of Translational Research and Pharmacogenomics. Dr. Peters received his medical degree from Freie Universität in Berlin, did a postdoctoral fellowship with Tak Wah Mak, PhD in Toronto, and has held teaching appointments in internal medicine and biochemistry at the University of Mainz.
“Tango has an impressive target discovery platform and drug development pipeline aimed at developing therapies for targets not addressed by other medicines,” Dr. Peters said. “I’m excited to take a seat on the board as they move toward the clinic with novel targeted therapies for patients with limited treatment options.”
About Tango Therapeutics
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of targeted therapies to people with cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer for patients with limited treatment options. The company is focused on three core areas: counteracting tumor suppressor gene loss, reversing the ability of cancer cells to evade the immune system and identifying novel combinations that will be more effective than single agent therapy. Tango was launched in 2017 with a $55 million Series A investment funded by Third Rock Ventures and was a 2017 “Fierce 15” company. For more information, please visit www.tangotx.com.